

# Global Postpartum Depression Drugs Market Size study, by Type (Postpartum Blues, Anxiety, PTSD), by Treatment (Pharmacotherapy, Hormonal Therapy), by Route of Administration, by Distribution Channel, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G71DBEFCD95BEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G71DBEFCD95BEN

## Abstracts

Global Postpartum Depression Drugs Market is valued approximately at USD 0.83 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 9.63% over the forecast period 2024-2032. Postpartum depression (PPD), a complex mood disorder occurring after childbirth, is now garnering critical attention on global healthcare agendas due to its deep psychological, emotional, and physiological impact on new mothers. As modern medical systems acknowledge the profound implications of maternal mental health on both parent and child, the market for postpartum depression drugs is witnessing steady expansion. Groundbreaking developments in neuropsychiatric therapeutics—particularly the advent of rapid-acting antidepressants—have reignited research, investment, and demand in this space. Additionally, the increasing destigmatization of postpartum mood disorders is fostering a supportive environment for clinical intervention, diagnosis, and treatment uptake across diverse demographic profiles.

The market's upward trajectory is further catalyzed by the widespread adoption of pharmacotherapy, particularly SSRIs (selective serotonin reuptake inhibitors), SNRIs, and new classes of neurosteroids, which are demonstrating rapid-onset efficacy. The FDA's approval of breakthrough therapies such as brexanolone and zuranolone underscores the shift toward novel mechanisms of action targeting GABA-A receptors, specifically designed for postpartum depression. While hormonal fluctuations remain central to PPD pathogenesis, pharmacological interventions are increasingly being tailored to individual biochemical profiles, facilitated by advances in genetic and

hormonal biomarker testing. At the same time, hormonal therapy regimens—especially those involving estrogen and progesterone modulation—are gaining clinical traction as adjunct or standalone treatments for specific PPD subtypes.

One of the market's most compelling transitions is the growing focus on route of administration, with innovations extending beyond traditional oral tablets to include intravenous infusions and intranasal formulations. These approaches not only optimize bioavailability and speed of action but also address patient-centric variables like convenience and compliance. Simultaneously, distribution channels are evolving, with a surge in hospital-based prescriptions, retail pharmacy access, and telemedicine-enabled drug delivery frameworks. In tandem, awareness campaigns led by government health bodies, NGOs, and advocacy groups are enhancing early screening rates, prompting earlier and more effective intervention strategies.

On the research and development front, a concerted push is being observed in clinical pipeline activity, with numerous biotech firms and pharmaceutical giants investing in second-generation neurosteroids, receptor modulators, and combination therapies. Cross-sector collaborations between academic institutions, women's health organizations, and drug developers are fueling translational research, while favorable regulatory pathways such as fast-track designation and priority review are expediting product approvals. Moreover, the role of real-world evidence and post-marketing surveillance is becoming increasingly significant in shaping drug formulations and labeling strategies that respond directly to patient feedback.

Regionally, North America commands the largest share of the postpartum depression drugs market, buoyed by high awareness levels, an established mental healthcare framework, and aggressive drug development pipelines. The U.S., in particular, exhibits strong reimbursement policies and early adoption of FDA-approved PPD therapies, making it a focal point for innovation and commercialization. Europe closely follows, with countries such as the UK, Germany, and France implementing progressive maternal mental health initiatives and national PPD screening programs. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by improved access to maternal healthcare, growing awareness of perinatal mental health, and a rising number of women entering the workforce—factors that increase healthcare engagement and diagnosis rates.

Major market player included in this report are:

Sage Therapeutics, Inc.

Pfizer Inc.

GlaxoSmithKline plc

Eli Lilly and Company

Novartis AG

Johnson & Johnson

Merck & Co., Inc.

H. Lundbeck A/S

Bausch Health Companies Inc.

AbbVie Inc.

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

Viartis Inc.

Takeda Pharmaceutical Company Limited

Sun Pharmaceutical Industries Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type

Postpartum Blues

Anxiety

PTSD

## By Treatment

Pharmacotherapy

Hormonal Therapy

## By Route of Administration

Oral

Intravenous

Others

## By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

## By Region:

### North America

U.S.

Canada

### Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

## Contents

### **CHAPTER 1. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET EXECUTIVE SUMMARY**

- 1.1. Global Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Type
  - 1.3.2. By Treatment
  - 1.3.3. By Route of Administration
  - 1.3.4. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply-Side Analysis
    - 2.3.3.1. Availability of Therapeutic Agents
    - 2.3.3.2. Manufacturing & Distribution Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Provider Perspective)
  - 2.3.4. Demand-Side Analysis
    - 2.3.4.1. Reimbursement & Insurance Frameworks
    - 2.3.4.2. Advances in Biomarker-Driven Diagnosis
    - 2.3.4.3. Patient Awareness & Advocacy
    - 2.3.4.4. Telehealth & Access to Care
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

## **CHAPTER 3. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET DYNAMICS**

### 3.1. Market Drivers

- 3.1.1. Rising Awareness & Screening Initiatives
- 3.1.2. Approval of Rapid-Acting Neurosteroids
- 3.1.3. Expansion of Telemedicine Platforms

### 3.2. Market Challenges

- 3.2.1. High Treatment Costs & Reimbursement Gaps
- 3.2.2. Stigma and Under-Diagnosis in Emerging Regions
- 3.2.3. Complexity of Hormonal and Neurochemical Pathways

### 3.3. Market Opportunities

- 3.3.1. Development of Intranasal & Fast-Onset Formulations
- 3.3.2. Growth of Online Pharmacy & DTC Channels
- 3.3.3. Collaborations on Biomarker-Guided Therapies

## **CHAPTER 4. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET INDUSTRY ANALYSIS**

### 4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Impact Analysis

### 4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### 4.3. Top Investment Opportunities

### 4.4. Top Winning Strategies

### 4.5. Disruptive Trends

### 4.6. Industry Expert Perspectives

### 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET SIZE & FORECASTS BY TYPE, 2022–2032**

- 5.1. Segment Dashboard
- 5.2. Postpartum Blues Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.3. Anxiety Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.4. PTSD Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

## **CHAPTER 6. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET SIZE & FORECASTS BY TREATMENT, 2022–2032**

- 6.1. Segment Dashboard
- 6.2. Pharmacotherapy Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.3. Hormonal Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

## **CHAPTER 7. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION, 2022–2032**

- 7.1. Segment Dashboard
- 7.2. Oral Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.3. Intravenous Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.4. Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

## **CHAPTER 8. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL, 2022–2032**

- 8.1. Segment Dashboard
- 8.2. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.3. Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.4. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

## **CHAPTER 9. GLOBAL POSTPARTUM DEPRESSION DRUGS MARKET SIZE & FORECASTS BY REGION, 2022–2032**

- 9.1. North America
  - 9.1.1. U.S.
  - 9.1.2. Canada
- 9.2. Europe
  - 9.2.1. UK

- 9.2.2. Germany
- 9.2.3. France
- 9.2.4. Spain
- 9.2.5. Italy
- 9.2.6. Rest of Europe
- 9.3. Asia Pacific
  - 9.3.1. China
  - 9.3.2. India
  - 9.3.3. Japan
  - 9.3.4. Australia
  - 9.3.5. South Korea
  - 9.3.6. Rest of Asia Pacific
- 9.4. Latin America
  - 9.4.1. Brazil
  - 9.4.2. Mexico
  - 9.4.3. Rest of Latin America
- 9.5. Middle East & Africa
  - 9.5.1. Saudi Arabia
  - 9.5.2. South Africa
  - 9.5.3. Rest of Middle East & Africa

## **CHAPTER 10. COMPETITIVE INTELLIGENCE**

- 10.1. Key Company SWOT Analysis
  - 10.1.1. Sage Therapeutics, Inc.
  - 10.1.2. Pfizer Inc.
  - 10.1.3. GlaxoSmithKline plc
- 10.2. Top Market Strategies
- 10.3. Company Profiles
  - 10.3.1. Sage Therapeutics, Inc.
    - 10.3.1.1. Key Information
    - 10.3.1.2. Overview
    - 10.3.1.3. Financial (Subject to Data Availability)
    - 10.3.1.4. Product Summary
    - 10.3.1.5. Market Strategies
  - 10.3.2. Pfizer Inc.
  - 10.3.3. GlaxoSmithKline plc
  - 10.3.4. Eli Lilly and Company
  - 10.3.5. Novartis AG

- 10.3.6. Johnson & Johnson
- 10.3.7. Merck & Co., Inc.
- 10.3.8. H. Lundbeck A/S
- 10.3.9. Bausch Health Companies Inc.
- 10.3.10. AbbVie Inc.
- 10.3.11. Sanofi S.A.
- 10.3.12. Teva Pharmaceutical Industries Ltd.
- 10.3.13. Viartis Inc.
- 10.3.14. Takeda Pharmaceutical Company Limited
- 10.3.15. Sun Pharmaceutical Industries Ltd.

## **CHAPTER 11. RESEARCH PROCESS**

- 11.1. Research Process
  - 11.1.1. Data Mining
  - 11.1.2. Analysis
  - 11.1.3. Market Estimation
  - 11.1.4. Validation
  - 11.1.5. Publishing
- 11.2. Research Attributes

## I would like to order

Product name: Global Postpartum Depression Drugs Market Size study, by Type (Postpartum Blues, Anxiety, PTSD), by Treatment (Pharmacotherapy, Hormonal Therapy), by Route of Administration, by Distribution Channel, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G71DBEFCD95BEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G71DBEFCD95BEN.html>